Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
grade F 26.85 0.56% 0.15
NXTC closed up 0.56 percent on Thursday, October 17, 2019, on 1.87 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical NXTC trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 0.56%
Oversold Stochastic Weakness 0.56%
Wide Bands Range Expansion -1.07%
Oversold Stochastic Weakness -1.07%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.56%
Outside Day Range Expansion 2.56%
Wide Bands Range Expansion 2.56%

Older signals for NXTC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Medicine Health Biopharmaceutical Cancer Clinical Medicine Immunotherapy Cancer Treatments Non Small Cell Lung Cancer Tumor Virotherapy Ovarian Cancer Treatment Of Ovarian Cancer Metastasis Oncolytics Biotech Metastatic Solid Tumors Halozyme Immune Related Diseases Yale University
Is NXTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 44.69
52 Week Low 13.86
Average Volume 90,629
200-Day Moving Average 0.0
50-Day Moving Average 31.8186
20-Day Moving Average 31.0045
10-Day Moving Average 27.491
Average True Range 2.532
ADX 25.84
+DI 15.8814
-DI 24.5087
Chandelier Exit (Long, 3 ATRs ) 34.1383
Chandelier Exit (Short, 3 ATRs ) 32.996
Upper Bollinger Band 39.8942
Lower Bollinger Band 22.1148
Percent B (%b) 0.27
BandWidth 57.344579
MACD Line -1.965
MACD Signal Line -1.364
MACD Histogram -0.6009
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.48
Resistance 3 (R3) 29.42 28.49 29.04
Resistance 2 (R2) 28.49 27.82 28.52 28.90
Resistance 1 (R1) 27.67 27.40 28.08 27.73 28.75
Pivot Point 26.73 26.73 26.94 26.76 26.73
Support 1 (S1) 25.91 26.06 26.32 25.97 24.95
Support 2 (S2) 24.98 25.65 25.01 24.80
Support 3 (S3) 24.16 24.98 24.66
Support 4 (S4) 24.22